Global Leukemia Therapeutics Market Size To Exceed USD 51.45 Billion By 2035 | CAGR Of 8.05%
Category: HealthcareGlobal Leukemia Therapeutics Market Size To Exceed USD 51.45 Billion By 2035
According to a research report published by Spherical Insights & Consulting, The Global Leukemia Therapeutics Market Size is expected to Grow from USD 21.95 Billion in 2024 to USD 51.45 Billion by 2035, at a CAGR of 8.05% during the forecast period 2025-2035.
Get more details on this report -
Browse 241 Market Data Tables And 45 Figures Spread Through 120 Pages and In-Depth TOC On the "Global Leukemia Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Type of Leukemia (Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, and Others), By Treatment (Chemotherapy, Immunotherapy, Targeted Therapy, Car-T Cell Therapy, and Others), By Route of Administration (Oral and Injectable), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/leukemia-therapeutics-market
The Leukemia Therapeutics Market Size is the industry that emphasises the development, production, and sale of therapies for leukemia, which is a type of cancer affecting the blood and bone marrow. Leukemia is characterized by an increasing number of abnormal blood cells, called blasts or leukemia cells. Treatment includes a combination of chemotherapy, radiation therapy, targeted therapy, and bone marrow transplant, with supportive and palliative care provided as needed. Further, there is ongoing development of novel therapeutic strategies and targeted drugs, making remarkable improvements and a need for developing preventive strategies. The increasing development in targeted therapies and immunotherapies in leukemia treatments is providing growth opportunities in leukemia therapeutics market. The increasing prevalence of leukemia and its mortality rates are driving the market demand for leukemia therapeutics. Further, increasing organizational funding for developing advanced therapeutics is supporting market growth. However, the several side effects of leukemia therapies and limited patient accessibility to expensive therapies are hindering the market.
The chronic lymphocytic leukemia segment dominated the market with a 31.7% market share in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the type of leukemia, the leukemia therapeutics market is divided into chronic myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, acute myeloid leukemia, and others. Among these, the chronic lymphocytic leukemia segment dominated the market with a 31.7% market share in 2024 and is projected to grow at a substantial CAGR during the forecast period. Chronic lymphocytic leukemia, accounts for 4.7 per 100,000 men and women per year, as per NCI estimates. An increasing innovations in targeted therapies, along with the expanded research in immunotherapy solutions, and increasing drug approvals are driving the market.
The targeted therapy segment accounted for the largest revenue share of 40.2% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the treatment, the leukemia therapeutics market is divided into chemotherapy, immunotherapy, targeted therapy, CAR-T cell therapy, and others. Among these, the targeted therapy segment accounted for the largest revenue share of 40.2% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. The segment includes novel tyrosine kinase inhibitors and monoclonal antibodies that focus on cell changes that are responsible for causing cancer. Increasing advancements in precision medicine and favourable regulatory policies for novel therapy approvals are supporting the market
The injectable segment accounted for the largest revenue share of 66.9% in 2024 and is anticipated to grow at a significant CAGR during the forecast period.
Based on the route of administration, the leukemia therapeutics market is divided into oral and injectable. Among these, the injectable segment accounted for the largest revenue share of 66.9% in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Traditional chemotherapy agents, targeted therapies, immunotherapies, and enzyme-based asparaginase treatments are administered via the injectable route. Its ease of absorption and quick outcomes are responsible for market growth.
North America is expected to hold the majority share of the global leukemia therapeutics market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of the global leukemia therapeutics market, accounting 45.5% share during the forecast period. The region's developed healthcare infrastructure and emphasis on developing advanced therapeutics are responsible for driving leukemia therapeutics market. The significant investment in the development of advanced therapies, such as CAR-T cell therapies, as well as increased emphasis on AI integration in drug development, are promoting market growth.
Asia Pacific is anticipated to grow at the fastest pace of 11.2% CAGR in the global leukemia therapeutics market during the forecast period. This is attributed to an increasing collaborative approach for advancing disease prevention, research, and patient care. With an increasing prevalence of leukemia, technological development and emphasis on the biosimilars approach are contributing to driving the market of leukemia therapeutics.
Major vendors in the global leukemia therapeutics market are Amgen Inc., Novartis, Sanofi/ Genzyme Corporation, F. Hoffmann-La Roche, Bristol-Myers Squibb, Pfizer Inc., Lupin Ltd., AbbVie, Johnson & Johnson Services, Inc., Takeda Pharmaceutical Co. Ltd., and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In October 2025, CytoMed Therapeutics Limited, a Singapore-based clinical stage biopharmaceutical company, develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced the publication of a preclinical study, in a research article entitled "Donor-Derived T Cells for Acute Myeloid Leukemia: A Promising "off-the-shelf” Immunotherapy Approach.”
- In September 2025, Made Scientific and Hemogenyx Pharmaceuticals plc announced a manufacturing partnership to advance HG-CT-1, Hemogenyx's Chimeric Antigen Receptor T-cell (CAR-T) therapy and lead clinical program for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) in adults.
- In August 2025, Intas Pharmaceuticals, in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as one of the world's leading suppliers of pegfilgrastim following the successful acquisition of UDENYCA (pegfilgrastim-cbqv) from Coherus BioSciences, Inc.
- In June 2025, the University of Cincinnati Cancer Center (UC), The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) and Jabez Biosciences are partnering to open a new phase 1 clinical trial studying JBZ-001, a potential new treatment for acute myeloid leukemia (AML).
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the leukemia therapeutics market based on the below-mentioned segments:
Global Leukemia Therapeutics Market, By Type of Leukemia
- Chronic Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Acute Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Others
Global Leukemia Therapeutics Market, By Treatment
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- CAR-T Cell Therapy
- Others
Global Leukemia Therapeutics Market, By Route of Administration
- Oral
- Injectable
Global Leukemia Therapeutics Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?